Neuropharma SA, a subsidiary of Zeltia Group, raised €16 million in its first external funding round to progress several preclinical programs in Alzheimer’s disease.
Neuropharma SA, a subsidiary of Zeltia Group, raised €16 million in its first external funding round to progress several preclinical programs in Alzheimer’s disease.
